BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 38192996)

  • 1. Establishment and validation of a prognostic immune-related lncRNA risk model for acute myeloid leukemia.
    Xie KY; Chen SZ; Wang Y; Zeng ML; Liu XY; Liang Y; Wei J
    Transl Cancer Res; 2023 Dec; 12(12):3693-3702. PubMed ID: 38192996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of seven novel ferroptosis-related long non-coding RNA signatures as a diagnostic biomarker for acute myeloid leukemia.
    Zheng Z; Wu W; Lin Z; Liu S; Chen Q; Jiang X; Xue Y; Lin D
    BMC Med Genomics; 2021 Sep; 14(1):236. PubMed ID: 34579730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DesA Prognostic Risk Model of LncRNAs in Patients With Acute Myeloid Leukaemia Based on TCGA Data.
    Ding W; Ling Y; Shi Y; Zheng Z
    Front Bioeng Biotechnol; 2022; 10():818905. PubMed ID: 35265597
    [No Abstract]   [Full Text] [Related]  

  • 4. A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for acute myeloid leukemia.
    Li P; Li J; Wen F; Cao Y; Luo Z; Zuo J; Wu F; Li Z; Li W; Wang F
    Front Oncol; 2022; 12():966920. PubMed ID: 36276132
    [TBL] [Abstract][Full Text] [Related]  

  • 5. N6-Methyladenosine-Related lncRNAs Are Novel Prognostic Markers and Predict the Immune Landscape in Acute Myeloid Leukemia.
    Zhang L; Ke W; Hu P; Li Z; Geng W; Guo Y; Song B; Jiang H; Zhang X; Wan C
    Front Genet; 2022; 13():804614. PubMed ID: 35615374
    [No Abstract]   [Full Text] [Related]  

  • 6. Cuproptosis-related lncRNA signature for prognostic prediction in patients with acute myeloid leukemia.
    Zhu Y; He J; Li Z; Yang W
    BMC Bioinformatics; 2023 Feb; 24(1):37. PubMed ID: 36737692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a novel defined inflammation-related long noncoding RNA signature contributes to predicting prognosis and distinction between the cold and hot tumors in bladder cancer.
    Xiong X; Chen C; Li X; Yang J; Zhang W; Wang X; Zhang H; Peng M; Li L; Luo P
    Front Oncol; 2023; 13():972558. PubMed ID: 37064115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and validation of endocrine resistance-related and immune-related long non-coding RNA (lncRNA) signatures for predicting endocrinotherapy response and prognosis in breast cancer.
    Yang M; Sun Y; Ji H; Zhang Q
    Ann Transl Med; 2022 Dec; 10(24):1399. PubMed ID: 36660659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cuproptosis-related lncRNAs forecast the prognosis of acute myeloid leukemia.
    Zhang T; Liao D; Hu Y
    Transl Cancer Res; 2023 May; 12(5):1175-1195. PubMed ID: 37304546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. m6A genotypes and prognostic signature for assessing the prognosis of patients with acute myeloid leukemia.
    Fu C; Kou R; Meng J; Jiang D; Zhong R; Dong M
    BMC Med Genomics; 2023 Aug; 16(1):191. PubMed ID: 37596597
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer.
    Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M
    Front Immunol; 2022; 13():891175. PubMed ID: 35990668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comprehensive Metabolism-Related Gene Signature Predicts the Survival of Patients with Acute Myeloid Leukemia.
    Zhai Y; Shen H; Wei H
    Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38254953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of a Prognostic Immune-Related LncRNA Risk Model for Lung Adenocarcinoma.
    Li Y; Shen R; Wang A; Zhao J; Zhou J; Zhang W; Zhang R; Zhu J; Liu Z; Huang JA
    Front Cell Dev Biol; 2021; 9():648806. PubMed ID: 33869203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel chemokine related LncRNA signature correlates with the prognosis, immune landscape, and therapeutic sensitivity of esophageal squamous cell cancer.
    Zhang Z; Wang J; Han W; Zhao L
    BMC Gastroenterol; 2023 Apr; 23(1):132. PubMed ID: 37081402
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Construction of Competitive Endogenous RNA Network and Verification of 3-Key LncRNA Signature Associated With Distant Metastasis and Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma.
    Su Y; Zhang T; Tang J; Zhang L; Fan S; Zhou J; Liang C
    Front Oncol; 2021; 11():640150. PubMed ID: 33869028
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognosis analysis and validation of lipid metabolism-associated lncRNAs and tumor immune microenvironment in bladder cancer.
    Tan Z; Fu S; Zuo J; Wang J; Wang H
    Aging (Albany NY); 2023 Aug; 15(16):8384-8407. PubMed ID: 37632832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive analysis of cuproptosis-associated LncRNAs predictive value and related CeRNA network in acute myeloid leukemia.
    Cao C; Wang T; Luo Y; Zhang Y; Dai YY; Shen Y
    Heliyon; 2023 Dec; 9(12):e22532. PubMed ID: 38058427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of m6A-Related lncRNAs Associated With Prognoses and Immune Responses in Acute Myeloid Leukemia.
    Li D; Liang J; Cheng C; Guo W; Li S; Song W; Song Z; Bai Y; Zhang Y; Wu X; Zhang W
    Front Cell Dev Biol; 2021; 9():770451. PubMed ID: 34869365
    [No Abstract]   [Full Text] [Related]  

  • 19. Construction of a ferroptosis-related five-lncRNA signature for predicting prognosis and immune response in thyroid carcinoma.
    Qin Y; Zhang D; Zhang H; Hou L; Wang Z; Yang L; Zhang M; Zhao G; Yao Q; Ling R; Zhang J
    Cancer Cell Int; 2022 Sep; 22(1):296. PubMed ID: 36175889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of circRNA-lncRNA-miRNA-mRNA Competitive Endogenous RNA Network as Novel Prognostic Markers for Acute Myeloid Leukemia.
    Cheng Y; Su Y; Wang S; Liu Y; Jin L; Wan Q; Liu Y; Li C; Sang X; Yang L; Liu C; Wang Z
    Genes (Basel); 2020 Jul; 11(8):. PubMed ID: 32751923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.